摘要
为了更好地理解2019年版《慢性乙型肝炎防治指南》,指导临床实践,本文对2019年版指南进行了解读与思考,并重点对2019年版与2015年版指南在临床诊断指标的变化、抗病毒治疗策略的调整以及特殊患者治疗推荐意见等方面的要点进行了介绍和分析。2019版指南在治疗上进一步扩大抗病毒治疗指征,强调了强效低耐药作为一线药物的推荐,对于特殊人群的指导意见更详细。
The paper intends to interpret 2019 Guideline of Prevention and Treatment for Chronic Hepatitis B.In order to better understand the guideline(2019 edition)and guide clinical practice,we highlighted the differences between the version of 2019 and 2015 pertinent to the changes in clinical diagnostic indicators,modified antiviral treatment strategies,and the treatment recommendations for special patients.The indications for antiviral therapy are further expanded,in which recommendation of potent agent with low resistance as first-line drugs is emphasized,and the guidance to medication of special population is specified.
作者
刘磊
李磊
LIU Lei;LI Lei(Department of Infectious Disease,the First Affiliated Hospital of University of Science and Technology of China(Anhui Provincial Hospital),Hefei 230001,China)
出处
《热带病与寄生虫学》
2020年第2期75-80,共6页
Journal of Tropical Diseases and Parasitology
基金
安徽省自然科学基金(1208085QH147)。
关键词
慢性乙型肝炎
抗病毒药
指南
解读
Chronic Hepatitis B
Antiviral agents
Guideline
Interpretation